Capital DailyCapital Daily
Markets · Investing · Business
Capital DailyCapital Daily
Finance

FDA advisers vote against sleep peptide as they debate safety and health claims

The FDA’s advisory committee is meeting for two days to discuss whether seven peptides — which have become popular in wellness circles — should be allowed to be compounded.

FDA advisers vote against sleep peptide as they debate safety and health claims

Published July 24, 2026 · Category: Finance

Overview

The FDA’s advisory committee is meeting for two days to discuss whether seven peptides — which have become popular in wellness circles — should be allowed to be compounded.

Source

Originally published at www.marketwatch.com.

Related Articles

CD
Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.